Education
About Us
Working with TipRanks
Follow Us
Pacira Pharmaceuticals (PCRX)
NASDAQ:PCRX
Total Valuation
Pacira Pharmaceuticals has a market cap or net worth of $1.20B. The enterprise value is $1.08B.
Market Cap$1.20B
Enterprise Value$1.08B
Share Statistics
Pacira Pharmaceuticals has 46,276,240 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding46,276,240
Owned by Insiders2.79%
Owned by Institutions1.95%
Financial Efficiency
Pacira Pharmaceuticals’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -9.24%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.06
Return on Invested Capital (ROIC)-9.24%
Return on Capital Employed (ROCE)-0.06
Revenue Per Employee889.55K
Profits Per Employee-126.35K
Employee Count788
Asset Turnover0.45
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Pacira Pharmaceuticals is -8.75. Pacira Pharmaceuticals’s PEG ratio is 0.03.
PE Ratio-8.75
PS Ratio1.59
PB Ratio1.12
Price to Fair Value1.12
Price to FCF4.87
Price to Operating Cash Flow4.60
PEG Ratio0.03
Income Statement
In the last 12 months, Pacira Pharmaceuticals had revenue of 700.97M and earned -99.56M in profits. Earnings per share was -2.15.
Revenue700.97M
Gross Profit700.97M
Operating Income-73.37M
Pretax Income-63.11M
Net Income-99.56M
EBITDA29.12M
Earnings Per Share (EPS)-2.15
Cash Flow
In the last 12 months, operating cash flow was 189.39M and capital expenditures -10.64M, giving a free cash flow of 178.75M billion.
Operating Cash Flow189.39M
Free Cash Flow178.75M
Free Cash Flow per Share3.86
Dividends & Yields
Pacira Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.86
52-Week Price Change-5.07%
50-Day Moving Average24.60
200-Day Moving Average19.76
Relative Strength Index (RSI)54.67
Average Volume (3m)981.09K
Important Dates
Pacira Pharmaceuticals upcoming earnings date is Apr 30, 2025, TBA Not Confirmed.
Last Earnings DateFeb 27, 2025
Next Earnings DateApr 30, 2025
Ex-Dividend Date―
Financial Position
Pacira Pharmaceuticals as a current ratio of 2.40, with Debt / Equity ratio of 82.08%
Current Ratio2.40
Quick Ratio2.00
Debt to Market Cap0.56
Net Debt to EBITDA7.32
Interest Coverage Ratio-5.46
Taxes
In the past 12 months, Pacira Pharmaceuticals has paid 36.45M in taxes.
Income Tax36.45M
Effective Tax Rate-0.58
Enterprise Valuation
Pacira Pharmaceuticals EV to EBITDA ratio is 37.24, with an EV/FCF ratio of 6.07.
EV to Sales1.55
EV to EBITDA37.24
EV to Free Cash Flow6.07
EV to Operating Cash Flow5.73
Balance Sheet
Pacira Pharmaceuticals has $484.62M in cash and marketable securities with $25.05M in debt, giving a net cash position of $154.24M billion.
Cash & Marketable Securities$484.62M
Total Debt$25.05M
Net Cash$154.24M
Net Cash Per Share$3.33
Tangible Book Value Per Share$7.62
Margins
Gross margin is 71.60%, with operating margin of -10.47%, and net profit margin of -14.20%.
Gross Margin71.60%
Operating Margin-10.47%
Pretax Margin-9.00%
Net Profit Margin-14.20%
EBITDA Margin4.15%
EBIT Margin-7.09%
Analyst Forecast
The average price target for Pacira Pharmaceuticals is $34.29, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$34.29
Price Target Upside32.39% Upside
Analyst ConsensusHold
Analyst Count8
Revenue Growth Forecast3.85%
EPS Growth Forecast-339.15%